MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma
Identifieur interne : 003005 ( Main/Exploration ); précédent : 003004; suivant : 003006MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma
Auteurs : W. Oster [Allemagne] ; T. Forsthuber [Allemagne] ; H. H. Hennekeuser [Allemagne] ; H. Gamm [Allemagne] ; A. Lindemann [Allemagne] ; G. Schmitz [Allemagne] ; H. G. Fuhr [Allemagne] ; R. Hinterberger [Allemagne] ; H. Kreiter [Allemagne] ; W. Thoenes [Allemagne] ; F. Herrmann [Allemagne] ; R. Mertelsmann [Allemagne]Source :
- Blut [ 0006-5242 ] ; 1990-01-01.
Abstract
Summary: Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL.
Url:
DOI: 10.1007/BF01720198
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001145
- to stream Istex, to step Curation: 001034
- to stream Istex, to step Checkpoint: 001560
- to stream Main, to step Merge: 003611
- to stream Main, to step Curation: 003005
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma</title><author><name sortKey="Oster, W" sort="Oster, W" uniqKey="Oster W" first="W." last="Oster">W. Oster</name></author><author><name sortKey="Forsthuber, T" sort="Forsthuber, T" uniqKey="Forsthuber T" first="T." last="Forsthuber">T. Forsthuber</name></author><author><name sortKey="Hennekeuser, H H" sort="Hennekeuser, H H" uniqKey="Hennekeuser H" first="H. H." last="Hennekeuser">H. H. Hennekeuser</name></author><author><name sortKey="Gamm, H" sort="Gamm, H" uniqKey="Gamm H" first="H." last="Gamm">H. Gamm</name></author><author><name sortKey="Lindemann, A" sort="Lindemann, A" uniqKey="Lindemann A" first="A." last="Lindemann">A. Lindemann</name></author><author><name sortKey="Schmitz, G" sort="Schmitz, G" uniqKey="Schmitz G" first="G." last="Schmitz">G. Schmitz</name></author><author><name sortKey="Fuhr, H G" sort="Fuhr, H G" uniqKey="Fuhr H" first="H. G." last="Fuhr">H. G. Fuhr</name></author><author><name sortKey="Hinterberger, R" sort="Hinterberger, R" uniqKey="Hinterberger R" first="R." last="Hinterberger">R. Hinterberger</name></author><author><name sortKey="Kreiter, H" sort="Kreiter, H" uniqKey="Kreiter H" first="H." last="Kreiter">H. Kreiter</name></author><author><name sortKey="Thoenes, W" sort="Thoenes, W" uniqKey="Thoenes W" first="W." last="Thoenes">W. Thoenes</name></author><author><name sortKey="Herrmann, F" sort="Herrmann, F" uniqKey="Herrmann F" first="F." last="Herrmann">F. Herrmann</name></author><author><name sortKey="Mertelsmann, R" sort="Mertelsmann, R" uniqKey="Mertelsmann R" first="R." last="Mertelsmann">R. Mertelsmann</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B10EC8219A051B3D4CBDB4A37352030AB1A57EDC</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1007/BF01720198</idno><idno type="url">https://api.istex.fr/document/B10EC8219A051B3D4CBDB4A37352030AB1A57EDC/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001145</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001145</idno><idno type="wicri:Area/Istex/Curation">001034</idno><idno type="wicri:Area/Istex/Checkpoint">001560</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001560</idno><idno type="wicri:doubleKey">0006-5242:1990:Oster W:macop:b:chemotherapy</idno><idno type="wicri:Area/Main/Merge">003611</idno><idno type="wicri:Area/Main/Curation">003005</idno><idno type="wicri:Area/Main/Exploration">003005</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma</title><author><name sortKey="Oster, W" sort="Oster, W" uniqKey="Oster W" first="W." last="Oster">W. Oster</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Abteilung für Hämatologie, Klinikum der Johannes-Gutenberg-Universität, Langenbeckstrasse 1, D-6500, Mainz</wicri:regionArea><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Mayence</settlement></placeName></affiliation></author><author><name sortKey="Forsthuber, T" sort="Forsthuber, T" uniqKey="Forsthuber T" first="T." last="Forsthuber">T. Forsthuber</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Tumorzentrum Rheinland-Pfalz, D-6500, Mainz</wicri:regionArea><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Mayence</settlement></placeName></affiliation></author><author><name sortKey="Hennekeuser, H H" sort="Hennekeuser, H H" uniqKey="Hennekeuser H" first="H. H." last="Hennekeuser">H. H. Hennekeuser</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Medizinische Abteilung, Bruder-Krankenhaus, D-5500, Trier</wicri:regionArea><wicri:noRegion>Trier</wicri:noRegion><wicri:noRegion>Trier</wicri:noRegion></affiliation></author><author><name sortKey="Gamm, H" sort="Gamm, H" uniqKey="Gamm H" first="H." last="Gamm">H. Gamm</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Abteilung für Hämatologie, Klinikum der Johannes-Gutenberg-Universität, Langenbeckstrasse 1, D-6500, Mainz</wicri:regionArea><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Mayence</settlement></placeName></affiliation></author><author><name sortKey="Lindemann, A" sort="Lindemann, A" uniqKey="Lindemann A" first="A." last="Lindemann">A. Lindemann</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Abteilung für Hämatologie, Klinikum der Johannes-Gutenberg-Universität, Langenbeckstrasse 1, D-6500, Mainz</wicri:regionArea><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Mayence</settlement></placeName></affiliation></author><author><name sortKey="Schmitz, G" sort="Schmitz, G" uniqKey="Schmitz G" first="G." last="Schmitz">G. Schmitz</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Abteilung für Hämatologie, Klinikum der Johannes-Gutenberg-Universität, Langenbeckstrasse 1, D-6500, Mainz</wicri:regionArea><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Mayence</settlement></placeName></affiliation></author><author><name sortKey="Fuhr, H G" sort="Fuhr, H G" uniqKey="Fuhr H" first="H. G." last="Fuhr">H. G. Fuhr</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Medizinische Abteilung, Horst Schmitt-Kliniken, D-6200, Wiesbaden</wicri:regionArea><wicri:noRegion>Wiesbaden</wicri:noRegion><wicri:noRegion>Wiesbaden</wicri:noRegion></affiliation></author><author><name sortKey="Hinterberger, R" sort="Hinterberger, R" uniqKey="Hinterberger R" first="R." last="Hinterberger">R. Hinterberger</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Hämatologische Gemeinschaftspraxis, D-6500, Mainz</wicri:regionArea><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Mayence</settlement></placeName></affiliation></author><author><name sortKey="Kreiter, H" sort="Kreiter, H" uniqKey="Kreiter H" first="H." last="Kreiter">H. Kreiter</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Medizinische Abteilung, Städtisches Krankenhaus, D-6750, Kaiserslautern</wicri:regionArea><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Kaiserslautern</settlement></placeName></affiliation></author><author><name sortKey="Thoenes, W" sort="Thoenes, W" uniqKey="Thoenes W" first="W." last="Thoenes">W. Thoenes</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institut für Pathologie, Johannes-Gutenberg-Universität, D-6500, Mainz</wicri:regionArea><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Mayence</settlement></placeName></affiliation></author><author><name sortKey="Herrmann, F" sort="Herrmann, F" uniqKey="Herrmann F" first="F." last="Herrmann">F. Herrmann</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Abteilung für Hämatologie, Klinikum der Johannes-Gutenberg-Universität, Langenbeckstrasse 1, D-6500, Mainz</wicri:regionArea><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Mayence</settlement></placeName></affiliation></author><author><name sortKey="Mertelsmann, R" sort="Mertelsmann, R" uniqKey="Mertelsmann R" first="R." last="Mertelsmann">R. Mertelsmann</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Abteilung für Hämatologie, Klinikum der Johannes-Gutenberg-Universität, Langenbeckstrasse 1, D-6500, Mainz</wicri:regionArea><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Mayence</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Blut</title><title level="j" type="sub">Zeitschrift für die Gesamte Blutforschung</title><title level="j" type="abbrev">Blut</title><idno type="ISSN">0006-5242</idno><idno type="eISSN">1432-0584</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1990-01-01">1990-01-01</date><biblScope unit="volume">60</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="23">23</biblScope><biblScope unit="page" to="27">27</biblScope></imprint><idno type="ISSN">0006-5242</idno></series><idno type="istex">B10EC8219A051B3D4CBDB4A37352030AB1A57EDC</idno><idno type="DOI">10.1007/BF01720198</idno><idno type="ArticleID">BF01720198</idno><idno type="ArticleID">Art4</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-5242</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Rhénanie-Palatinat</li></region><settlement><li>Kaiserslautern</li><li>Mayence</li></settlement></list><tree><country name="Allemagne"><region name="Rhénanie-Palatinat"><name sortKey="Oster, W" sort="Oster, W" uniqKey="Oster W" first="W." last="Oster">W. Oster</name></region><name sortKey="Forsthuber, T" sort="Forsthuber, T" uniqKey="Forsthuber T" first="T." last="Forsthuber">T. Forsthuber</name><name sortKey="Fuhr, H G" sort="Fuhr, H G" uniqKey="Fuhr H" first="H. G." last="Fuhr">H. G. Fuhr</name><name sortKey="Gamm, H" sort="Gamm, H" uniqKey="Gamm H" first="H." last="Gamm">H. Gamm</name><name sortKey="Hennekeuser, H H" sort="Hennekeuser, H H" uniqKey="Hennekeuser H" first="H. H." last="Hennekeuser">H. H. Hennekeuser</name><name sortKey="Herrmann, F" sort="Herrmann, F" uniqKey="Herrmann F" first="F." last="Herrmann">F. Herrmann</name><name sortKey="Hinterberger, R" sort="Hinterberger, R" uniqKey="Hinterberger R" first="R." last="Hinterberger">R. Hinterberger</name><name sortKey="Kreiter, H" sort="Kreiter, H" uniqKey="Kreiter H" first="H." last="Kreiter">H. Kreiter</name><name sortKey="Lindemann, A" sort="Lindemann, A" uniqKey="Lindemann A" first="A." last="Lindemann">A. Lindemann</name><name sortKey="Mertelsmann, R" sort="Mertelsmann, R" uniqKey="Mertelsmann R" first="R." last="Mertelsmann">R. Mertelsmann</name><name sortKey="Schmitz, G" sort="Schmitz, G" uniqKey="Schmitz G" first="G." last="Schmitz">G. Schmitz</name><name sortKey="Thoenes, W" sort="Thoenes, W" uniqKey="Thoenes W" first="W." last="Thoenes">W. Thoenes</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003005 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003005 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B10EC8219A051B3D4CBDB4A37352030AB1A57EDC
|texte= MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma
}}
| This area was generated with Dilib version V0.6.31. |  |